Latest Asx Suspensions News

Yowie Group’s FY26 loss narrowed sharply after cost reductions and a non-cash loan impairment reversal, but revenue fell 27% and operating cash flow turned deeply negative. The confectionery maker remains loss-making, has negative net assets and faces uncertainty over funding, supply and the return of its ASX quotation.

ASX has immediately suspended quotation of Antilles Gold’s AAUOD securities pending compliance with Listing Rule 2.5. The notice does not disclose the underlying compliance issue or indicate when quotation may resume.

Metrics Real Estate Multi-Strategy Fund units will remain suspended on ASX after the fund failed to lodge its audited financial statements. Reinstatement now depends on the accounts being filed and ASX deciding that trading can resume appropriately.

ASX will keep Metrics Master Income Trust securities suspended after the trust failed to lodge its audited financial statements. Trading will not resume until the accounts are filed and ASX considers reinstatement appropriate.

Chimeric Therapeutics remains suspended from ASX trading after failing to lodge its FY2026 financial statements, with the company reporting an approximate $7.7 million net asset deficiency and unresolved creditor negotiations. Potential recapitalisation interest has emerged, but no binding funding or settlement agreement has been reached.

MCS Services has completed the sale of its Traffic Business and now has no operating business, while its ASX securities remain suspended pending a possible recompliance transaction. The company reported $1.77 million in cash at 30 June 2026, but also faces a $495,000 legal settlement and no recurring operating revenue.

xReality Group’s securities have been suspended from quotation after the company could not release its revised FY26 4E results while its annual accounts remain unaudited. The suspension is expected to continue until the audit is complete and the revised results and accounts are lodged.

TerraCom has been suspended from trading while it completes audited FY2026 results expected to include material impairments to its South African and Australian assets. The company has not yet disclosed the size or effect of those write-downs.

Paradigm Biopharmaceuticals has entered voluntary administration after its pivotal Phase 3 trial produced an interim efficacy result below the threshold required for continuation. The company’s securities will remain suspended while administrators assess its viability, liabilities and possible restructuring options.

Metrics Income Opportunities Trust has been suspended from trading after its responsible entity warned that the audited FY2026 financial report may differ materially from figures released in August. The final report is expected on 30 September, but the filing does not disclose the size or direction of the changes.

Metrics Real Estate Multi-Strategy Fund units have been suspended at the fund’s request after its responsible entity warned that the final audited 2026 financial report may differ materially from figures released in August. The report is expected on 30 September.

Metrics Master Income Trust has been suspended from trading after warning that its audited FY2026 financial report may differ materially from unaudited figures released last month. The final report is expected on 30 September, but the trust has not disclosed the nature or size of the revisions.